Shanghai EGT Synbio Group Selected for the 2026 Yangtze River Delta "One-Stop Application" List

Recently, the Shanghai Municipal Commission of Economy and Informatization, together with the industry and information technology authorities of Jiangsu, Zhejiang, and Anhui, jointly released the 2026 Yangtze River Delta Regional Key Products and Processes “One-Stop Application” List.

According to the official announcement, a total of 68 projects were collected during this selection process. After expert evaluation organized by the China Industrial Control Systems Cyber Emergency Response Team / National Industrial Information Security Development Research Center, 42 application projects were finally selected and published.

Shanghai EGT Synbio Group Co., Ltd. was selected as a participating organization in Project No. 35: “Synthetic Biology-Empowered Biomanufacturing Technology and Product Development of Natural Compounds.”

This selection reflects the recognition of Shanghai EGT Synbio Group’s integrated capabilities in the scalable biomanufacturing, product development, application validation, and market transformation of natural active compounds.

Authoritative Recognition: Why the Yangtze River Delta “One-Stop Application” Mechanism Matters

The Yangtze River Delta “One-Stop Application” mechanism is a regional industrial collaboration program jointly promoted by Shanghai, Jiangsu, Zhejiang, and Anhui. It focuses on key industrial foundation areas and aims to strengthen coordination among upstream and downstream players across the innovation chain and industrial chain.

Its goal is to accelerate the application of innovative products and advanced processes, while addressing bottlenecks such as “cannot be used,” “not easy to use,” and “do not know how to use” during industrial implementation.

For the synthetic biology industry, the value of this mechanism lies not only in individual technological breakthroughs, but also in connecting laboratory research with pilot-scale development, mass production, quality validation, regulatory registration, and downstream product applications.

Natural compound biomanufacturing is a typical long-chain industry. The upstream stage requires strain engineering and metabolic pathway optimization; the midstream stage requires fermentation scale-up and green separation and purification; the downstream stage requires safety evaluation, efficacy validation, compliance registration, formulation development, and market transformation. A weakness in any single link may affect the final commercialization process.

Q&A: What is the “One-Stop Application” List?

Q: What problem does the Yangtze River Delta “One-Stop Application” List aim to solve?
A: It aims to solve disconnects between research, pilot-scale validation, industrialization, and end-use application. The mechanism promotes collaboration among industrial partners, research institutions, pilot platforms, and downstream application companies.

Q: Why is inclusion in the list meaningful?
A: The list is selected through project collection, expert review, and publication by government authorities. Being selected indicates that the project has strong technical value, market relevance, and industrial collaboration potential.

Q: What does this mean for Shanghai EGT Synbio Group?
A: It means the company is not only a raw material supplier, but is also entering a broader regional industrial collaboration network, participating in the systematic commercialization of natural active compounds from R&D to market application.

Project Interpretation: Synthetic Biology Enables Efficient Biomanufacturing of Natural Compounds

In the 2026 Yangtze River Delta “One-Stop Application” plan, efficient biomanufacturing processes for natural compounds are listed under the category of advanced fundamental manufacturing processes.

This direction focuses on key industrial links in natural compound biomanufacturing, including the precise design and optimization of biological elements and efficient cell factories, intelligent control of large-scale fermentation, innovation in green separation and purification processes, product application development, safety and efficacy evaluation, and the construction of compliance registration systems.

The project specifically focuses on high-value natural active compounds such as S-equol, rare ginsenosides, and ergothioneine, aiming to break through core technical bottlenecks in scalable biomanufacturing and promote industrial demonstration and application in the health and wellness sector.

This aligns closely with the core technology pathway of Shanghai EGT Synbio Group.

Taking ergothioneine as an example, the ingredient has strong market attention and application potential. However, traditional natural extraction methods have long faced challenges such as low yield, high cost, difficult purification, and limited scalability. Through synthetic biology and fermentation-based manufacturing, rare natural active ingredients can move from resource-dependent extraction to controllable biomanufacturing, providing a new pathway for large-scale supply and domestic substitution.

In this project, Shanghai EGT Synbio Group contributes its key strengths in the scalable biomanufacturing of natural compounds, product development, efficacy evaluation, safety validation, application development, compliance registration, and market promotion. Together with upstream and downstream partners, the company helps build a closed-loop industrial chain.

                                                              Follow our WeChat official account for more information!